Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones October 31, 2023 CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers - Read More October 26, 2023 CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients - Read More October 16, 2023 CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation - Read More Load MoreLoadingMeet us at the following conferences & events ESMO I-O Congress 2023 Dec 6 - Dec 8, 2023 Geneva, Switzerland Read More JPM 2024 Jan 8 -Jan 11, 2024 San Francisco, CA, USA Read More IO 360° 2024 Feb 27 - Feb 29, 2024 New York, NY, USA Read More ASCO 2024 May 31 - June 4, 2024 Chicago, IL, USA Read More
